Alzheimer Disease

Research uncovers the crucial role of lipids and microglia in Alzheimer disease, revealing new therapeutic targets for treatment and brain health.

The 1-year extension period in trials will be discontinued based on the efficacy results observed in the overall study population, said Novo Nordisk.

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Compared with late postmenopausal women, menopausal hormone therapy (MHT) may influence certain Alzheimer disease-related biomarkers in early postmenopausal women.

BMS-986446 shows promise as a fast-tracked therapy for early Alzheimer disease, targeting tau protein to alter disease progression.

Anti-Amyloid Antibody Treatments, Subcutaneous Formulations, and Improved Symptom Relief Are Offering New Hope for Patients

The subcutaneous injection for maintenance treatment enhances accessibility and reduces infusion time for patients.

The new data highlight how dietary changes could fuel Alzheimer- and dementia-related mechanisms.

Harvard researchers reveal lithium deficiency as a potential early driver of Alzheimer disease, suggesting new treatment avenues for patients.

Intranasal insulin shows promise in targeting memory regions of the brain, offering new hope for Alzheimer disease treatment in older adults.

Donanemab-azbt shows sustained benefits in slowing cognitive decline in Alzheimer disease, emphasizing the value of early intervention and treatment.

FDA approves a new dosing schedule for donanemab, enhancing safety and efficacy in treating early symptomatic Alzheimer disease.

Recent research reveals that RSV and shingles vaccines significantly lower dementia risk, highlighting the potential benefits of AS01 adjuvants in vaccination.

Amyvid is used for brain imaging to estimate amyloid plaque density in patients with cognitive impairment undergoing evaluation for Alzheimer disease.

A recent meta-analysis reveals low persistence rates with anti-dementia drugs, highlighting factors influencing adherence and the need for standardized reporting.

The authors wrote that a life course approach to the treatment and prevention of depression may help reduce individual burdens of dementia.

The small molecule effectively blocks cell death effector proteins, potentially rescuing cells from degeneration.

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

A survey showed that 92% of Americans are open to treatments that would slow disease progression.

BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.

The study aims to assess how docosahexaenoic acid levels in cerebrospinal fluid relate to both neurodegeneration and cognitive function.

Pharmacists can support patients with treatment education, monitoring, and adherence, helping to overcome challenges posed by cognitive decline.

Supplements, such as Prevagen, as well as lifestyle and diet modifications can provide additional support to patients with Alzheimer disease.

Health care professionals, particularly pharmacists, can recommend that patients take over-the-counter supplements, such as melatonin, to facilitate REM sleep.